|
|
|
市場調查報告書
非侵入性產前診斷和新生兒篩檢的機會
Opportunities in Noninvasive Prenatal Diagnostics and Newborn Screening
|
非侵入性產前診斷和新生兒篩檢的機會 是由出版商Decision Resources, Inc.在2011年02月所出版的。
這份英文市場調查報告書價格從美金4600起跳。
推動使用非侵入性檢測儘早提高胎兒異常檢測，促使眾多廠商從事研發產前診斷和新生兒篩查。新一代測序技術是分子檢測結合基因檢測的最前線。分子診斷檢驗領域面臨相關法規和醫療方面的課題，對倫理，成本效益，盈利等方面也必須進行檢討。
本報告提供非侵入性產前診斷與新生兒篩檢市場相關調查分析，市場的未滿足需求，微創技術趨勢，新的技術開發，今後5年所關注的企業等資料彙整，為您概述以下內容。
摘要整理
簡介
未滿足需求的理解
- 胎兒的健康預測
- 早產預測
- 新生兒的安全性和確保健康
微創技術是目前染色體異常檢測的黃金法則
遺傳基因檢驗的法律規制
非侵入性技術的新的開發
專家的評語
今後5年，負責檢測的企業
- Fluidigm
- Sequenom
- Counsyl
- Hologic
- 今後預測
- 關於作者
- 相關報告
Abstract
Introduction:
The push to improve detection of fetal abnormalities as early as possible with
the use of noninvasive tests has prompted numerous manufacturers to engage in
R&D directed at prenatal diagnostics and newborn screening. Next-generation
sequencing techniques coupled with molecular assays are at the forefront of
the genetic testing boom, with the singular aim of optimally isolating fetal
DNA. It is at this juncture within the molecular diagnostic testing arena
where issues of science, regulatory oversight, and medical expertise must be
addressed and weighed against those related to ethics, cost-effectiveness, and
profitability.
Questions Answered in This Report:
- Current invasive prenatal diagnostics such as amniocentesis and chorionic
villus sampling (CVS) are still the preferred gold standard, but concerns
about cost and safety are creating opportunities for noninvasive detection of
chromosomal abnormalities. What noninvasive techniques are of most interest
at the preconception stage versus during pregnancy? What is the potential for
testing alongside in vitro fertilization (IVF)?
- Molecular diagnostics technologies including microarray and
next-generation sequencing have created tremendous growth opportunities in the
prenatal diagnostics market. While noninvasive testing will not replace
invasive prenatal testing completely, what breakthroughs have been achieved in
sensitivity of emerging prenatal tests? What companies and research
laboratories are reporting progress in this field?
- Advances in next-generation sequencing and molecular assay technologies
have led to opportunities in prenatal diagnostics, particularly in the area of
standardization. What role has sequencing played in strengthening
state-mandated newborn screening programs? How will they change in the future?
What condition is a federal advisory committee considering adding to the
universal panel?
- Ongoing research has shown that the entire fetal genome can be obtained
from maternal plasma. What is the potential for prenatal diagnostics and
newborn screening tests as a result of continued success in this arena?
Scope:
- Testing uses mentioned: Sex selection, cystic fibrosis (CF),
Fragile X syndrome, preeclampsia, Down' s syndrome, Noonan' s syndrome, Batten
disease, Duchenne muscular dystrophy, cleft lip, neural tube defects,
gastroschisis, clubfoot, intra-amniotic infection, congenital hypothyroidism,
biotinidase deficiency, sickle cell anemia, congenital adrenal hyperplasia,
phenylketonuria, Tay-Sachs disease, Huntington' s disease, polycystic kidney
disease (adult), hemophilia A, CHILD syndrome.
- Genes mentioned: CFTR, FMR1, CYP11B1, Hemoglobin beta gene (HBB),
HEXA, HTT, PKD1, Xp2l, FVIII, CPDX2.
- Issues explored: Preimplantation genetic diagnosis, universal
carrier testing, newborn screening, genetic counseling, in vitro
fertilization, next-generation sequencing.
- Expert Commentary: Decision Resources analyst Cindy Fung, Ph.D.,
discusses the cost and benefit considerations involved in prenatal diagnostics
for CF.
- Companies: Discussion of select companies in the field of prenatal
noninvasive testing that should be monitored over the next five years.
Table of Contents
- Executive Summary
- Strategic Considerations
- Stakeholder Implications
- Introduction
- Understanding the Unmet Needs
- Predicting the Health of a Fetus
- Predicting Preterm Delivery
- Ensuring Safety and Health for Newborns
- Sidebar: Invasive Methods Are Current Gold Standards for Detecting
Chromosome Abnormalities
- Regulatory Oversight of Genetic Testing
- Novel Developments in Noninvasive Techniques
- Preconception Stage
- Carrier Testing for Prospective Parents
- Preimplantation Genetic Diagnosis
- Pregnancy Stage
- Fetal DNA Analysis
- Preeclampsia
- Spectrum Expert Commentary: A Cost-Benefit Analysis of Preimplantation
Genetic Diagnosis for Cystic Fibrosis from the Payer' s Perspective
- Companies to Monitor Over the Next Five Years
- Fluidigm
- Sequenom
- Counsyl
- Hologic
- Outlook
- About the Author
- Look for relevant insight within these Spectrum series and related
Spectrum reports:
|
 |
